The inhibitory Fcγ-receptor IIB (CD32B) is highly expressed on clonal plasma cells from patients with systemic light-chain (AL) amyloidosis and provides a target for monoclonal antibody therapy

被引：0
|
作者：
Zhou, P.
Olshen, A. B.
Bonvini, E.
Koenig, S.
Fleisher, M.
Young, J.
Boruchov, A.
Comenzo, R. L.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] MacroGen Inc, Rockville, MD USA
来源：
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2006年 / 13卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：13 / 14
页数：2
相关论文
共 12 条
  • [1] The inhibitory Fcy-receptor IIB (CD32B) is highly expressed on clonal plasma cells from patients with systemic light-chain (AL) amyloidosis and provides a target for monoclonal antibody therapy
    Zhou, P.
    Olshen, A. B.
    Bonvini, E.
    Koenig, S.
    Fleisher, M.
    Young, J.
    Boruchov, A.
    Comenzo, R. L.
    XIth International Symposium on Amyloidosis, 2008, : 371 - 373
  • [2] CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy
    Zhou, Ping
    Comenzo, Raymond L.
    Olshen, Adam B.
    Bonvini, Ezio
    Koenig, Scott
    Maslak, Peter G.
    Fleisher, Martin
    Hoffman, James
    Jhanwar, Suresh
    Young, James W.
    Nimer, Stephen D.
    Boruchov, Adam M.
    BLOOD, 2008, 111 (07) : 3403 - 3406
  • [3] CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
    Rankin, Christopher T.
    Veri, Maria-Concetta
    Gorlatov, Sergey
    Tuaillon, Nadine
    Burke, Steve
    Huang, Ling
    Inzunza, H. David
    Li, Hua
    Thomas, Shannon
    Johnson, Syd
    Stavenhagen, Jeffrey
    Koenig, Scott
    Bonvini, Ezio
    BLOOD, 2006, 108 (07) : 2384 - 2391
  • [4] CD32B on clonal plasma cells in systemic light-chain amyloidosis (AL) and multiple myeloma (MM): A target for immunotherapy in both disorders and a prognostic marker in MM.
    Boruchov, Adam
    Zhou, P.
    Olshen, A.
    Rankin, C.
    Bonvini, E.
    Koenig, S.
    Fleisher, M.
    Rose, R.
    McKenzie, S.
    Maslak, Peter
    Jhanwar, Suresh C.
    Young, James W.
    Nimer, Stephen D.
    Comenzo, Raymond
    BLOOD, 2006, 108 (11) : 995A - 995A
  • [5] Immunotherapy Targeting Inhibitory Fcγ Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization
    Williams, Emily L.
    Tutt, Alison L.
    Beers, Stephen A.
    French, Ruth R.
    Chan, Claude H. T.
    Cox, Kerry L.
    Roghanian, Ali
    Penfold, Christine A.
    Butts, Cherie L.
    Boross, Peter
    Verbeek, J. Sjef
    Cragg, Mark S.
    Glennie, Martin J.
    JOURNAL OF IMMUNOLOGY, 2013, 191 (08): : 4130 - 4140
  • [6] An Fc-optimized monoclonal antibody against CD32B, the human inhibitory Fc-γreceptor IIB, in the immunotherapy of B-cell malignanacy.
    Stavenhagen, Jeffrey B.
    Gorlatov, Sergey
    Tuaillon, Nadine
    Rankin, Christopher T.
    Veri, Maria-Concetta
    Inzunza, David
    Burke, Stephen
    Huang, Ling
    Li, Hua
    Thomas, Shannon
    Johnson, Syd
    Ravetch, Jeffrey
    Koenig, Scott
    Bonvini, Ezio
    BLOOD, 2006, 108 (11) : 715A - 715A
  • [7] Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A):: biochemical, biological and functional characterization
    Veri, Maria-Concetta
    Gorlatov, Sergey
    Li, Hua
    Burke, Steve
    Johnson, Syd
    Stavenhagen, Jeffrey
    Stein, Kathryn E.
    Bonvini, Ezio
    Koenig, Scott
    IMMUNOLOGY, 2007, 121 (03) : 392 - 404
  • [8] Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan
    Zhou, Ping
    Teruya-Feldstein, Julie
    Lu, Ping
    Fleisher, Martin
    Olshen, Adam
    Comenzo, Raymond L.
    BLOOD, 2008, 111 (02) : 549 - 557
  • [9] A supervised analysis of gene-expression profiles of purified clonal plasma cells from patients with systemic light-chain amyloidosis (AL) who have high or low levels of serum free lambda light chains
    Comenzo, R. L.
    Zhou, P.
    Fleisher, M.
    Olshen, A. B.
    XIth International Symposium on Amyloidosis, 2008, : 237 - 239
  • [10] A supervised analysis of gene-expression profiles of purified clonal plasma cells from patients with systemic light-chain amyloidosis (AL) who have high or low levels of serum free lambda light chains
    Comenzo, R. L.
    Zhou, P.
    Fleisher, M.
    Olshen, A. B.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2006, 13 : 23 - 24
12